Lyopan® is a proprietary technology for development and manufacture of fast-dissolve lyophilized tablets, including over-the-counter (OTC) products such as allergy treatments or travel medications. Lyopan® also requires significantly less water than existing technology, an advantage that helps reduce energy consumption, sublimation and drying time. As a result of these advanced characteristics, Lyopan® technology offers the potential for improved taste-masking capabilities and may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form.
The acquisition of Lyopan® technology is the latest example of Catalent's ongoing investment in advanced oral dose solutions and novel technologies. It advances Catalent's oral dose capabilities, potentially enabling the delivery of improved, compliance-enhancing treatments across a broad range of applications, including central nervous system drugs, allergy medications, and dosage forms for pediatric and geriatric populations. Additionally, Lyopan® technology lends itself easily to the development of both prescription and OTC products.
“With its long history of developing lyophilized fast-dissolve products, Catalent is the ideal partner to launch our innovative Lyopan® technology,” commented Hans Peter Rohrer, Chairman of Pantec.
The acquisition of Lyopan® technology also has clear synergies with several of Catalent's existing technologies, such as Zydis® fast dissolve, a unique, freeze-dried oral solid dosage form that disperses instantly in the mouth, without requiring water.
Catalent's Modified Release Technologies business provides the most oral dosage-form solutions with innovative, advanced formulation and process technologies, including tablets, capsules and other formulations for sustained or modified release. Catalent has a proven record of introducing advanced orally disintegrating tablet (ODT) technologies to the market, including Zydis® fast dissolve.